About Rhaeos
Rhaeos is a company based in Evanston (United States) founded in 2018 by Amit Ayer, Siddharth Krishnan, and John Rogers. It operates as a HealthTech. Rhaeos has raised $12.8 million across 9 funding rounds from investors including NIH, HHS and Northwestern University. The company has 10 employees as of December 31, 2022. Rhaeos offers products and services including FlowSense. Rhaeos operates in a competitive market with competitors including Ceribell, Kernel, NeuroKaire, Seer and Therma, among others.
- Headquarter Evanston, United States
- Employees 10 as on 31 Dec, 2022
- Founders Amit Ayer, Siddharth Krishnan, John Rogers
-
Sectors
TechnologyHealthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Rhaeos, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$12.8 M (USD)
in 9 rounds
-
Latest Funding Round
$306.52 K (USD), Grant
Sep 15, 2024
-
Investors
NIH
& 14 more
-
Employee Count
10
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Rhaeos
Rhaeos offers a comprehensive portfolio of products and services, including FlowSense.
FlowSense assesses hydrocephalus shunt flow in minutes.
People of Rhaeos
Unlock access to complete
Unlock access to complete
Funding Insights of Rhaeos
Rhaeos has successfully raised a total of $12.8M across 9 strategic funding rounds. The most recent funding activity was a Grant round of $306.52 thousand completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Rhaeos
Rhaeos has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and Northwestern University.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Venture capital fund focused on multiple sectors
|
Locked | Locked | Locked | |
|
Creative Ventures is focused on deep tech venture investments.
|
Locked | Locked | Locked |
Investor details for Rhaeos
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Rhaeos
Investment portfolio details for Rhaeos
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Rhaeos
Detailed financials for Rhaeos
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Rhaeos Comparisons
Peer comparison for Rhaeos
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Rhaeos
Rhaeos operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ceribell, Kernel, NeuroKaire, Seer and Therma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Portable EEG devices for point-of-care seizure diagnosis are provided.
|
|
| Locked | Locked | Locked |
Multimodal brain measurement technology is developed for neuromedicine applications.
|
|
| Locked | Locked | Locked |
Platform offering personalized treatment for psychiatric and neurological conditions
|
|
| Locked | Locked | Locked |
Proteomics platform developed for early cancer and neurological disease detection.
|
|
| Locked | Locked | Locked |
Solutions for temperature, humidity, and energy monitoring are provided.
|
|
| Locked | Locked | Locked |
Wearable devices and app are provided for mental disorder support.
|
Detailed competitors of Rhaeos
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Rhaeos
Complete news archive for Rhaeos
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rhaeos
Rhaeos was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Rhaeos is headquartered in Evanston, United States. It is registered at Evanston, Illinois, United States.
Anna Lisa Somera is the current CEO of Rhaeos.
Rhaeos is a funded company, having raised a total of $12.8M across 9 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Rhaeos is 10.
Rhaeos is engaged in the development of non-invasive, wireless, and wearable medical devices for hydrocephalus patients. Their primary product, FlowSense, is designed to assess shunt flow in minutes, addressing challenges in detecting shunt malfunctions. The company operates within the healthcare sector, targeting solutions for neurological conditions. Collaborations with various partners and participation in clinical events are maintained to advance their investigational devices. Their technology aims to reduce readmission rates and emergency department visits for hydrocephalus patients in the United States.
Rhaeos's top competitors include Ceribell, CND Life Sciences and Therma.
Rhaeos offers FlowSense.
Rhaeos has 15 investors. Key investors include NIH, HHS, Northwestern University, Gener8tor, and Artistic Ventures.